Sharekhan

Medicamen Biotech Ltd

Tue 1/07/2025,14:49:56 NSE: MEDICAMEQ

₹ 411.30 -5.05 (-1.21%)
BUY NOW Buy Medicamen Biotech Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Medicamen Biotech Ltd

Tue 1/07/2025,15:2:0

Medicamen Biotech Ltd

Tue 1/07/2025,14:49:56 | NSE : MEDICAMEQ

₹ 411.30-5.05 (-1.21%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 416.50

Previous Close

₹ 416.35

Volume

9700

Mkt Cap ( Rs. Cr)

₹557.91

High

₹ 420.00

Low

₹ 410.25

52 Week High

₹ 630.00

52 Week Low

₹ 375.05

Book Value Per Share

₹ 159.80

Dividend Yield

0.24

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Medicamen Biotech Ltd

Your Vote -

Buy

60.00%

Hold

0.00%

Sell

40.00%

60.00%

5 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

68%

Sell Order Quantity

32%

Bid Price

Qty

411.60

4

411.00

4

411.00

1

411.00

11

411.00

91

Bid Total

27148

Bid Price

Qty

412.10

6

412.00

4

412.00

14

412.00

1

412.00

14

Bid Total

12571

Option Chain

Analyzes market sentiment, predicts Medicamen Biotech Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Medicamen Biotec - General Updates

    3 Jun 2025, 12:57PM Medicamen Biotech Limited has informed the Exchange about General Updates- Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure

  • Medicamen Biotec - Copy of Newspaper Publication

    2 Jun 2025, 11:55AM Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication

  • Medicamen Biotec - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    31 May 2025, 5:52PM MEDICAMEN BIOTECH LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer A

  • Medicamen Biotec - Outcome of Board Meeting-XBRL

    31 May 2025, 5:20PM MEDICAMEN BIOTECH LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 30-May-2025 for Dividend

  • Medicamen Biotec Q4 net profit down 22.26% at Rs 2.41 cr

    30 May 2025, 9:36PM The company reported standalone net profit of Rs 2.41 crore for the quarter ended March 31, 2025 as compared to Rs 3.10 crore in the same period last

  • Medicamen Biotec - Dividend

    30 May 2025, 9:08PM Medicamen Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 30, 2025, recommended Final Dividend of 1 per e

  • Medicamen Biotec - Outcome of Board Meeting

    30 May 2025, 9:07PM Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

  • Medicamen Biotec - Financial Results Year Ended On 31.03.2025

    30 May 2025, 9:02PM Financial Results year ended on 31.03.2025

  • Medicamen Biotec - Board Meeting Intimation

    22 May 2025, 5:01PM MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2025 to consider and approve the Yearly Audited Financial

  • Medicamen Biotec - Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange

    22 May 2025, 4:56PM Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider a

  • Medicamen Biotec has submitted to BSE the Shareholding Pattern for the Period Ended April 24, 2025

    2 May 2025, 7:01AM As of April 2025, 40.46% is owned by Indian Promoters and 59.54% by Public. <p align=justify> Top Promoter holding highest number of shares of Medicam

  • Medicamen Biotec - Updates

    25 Apr 2025, 6:00PM Medicamen Biotech Limited has informed the Exchange regarding 'Corrigendum to the Outcome of the Meeting of Board of Directors of Medicamen Biotech Li

  • Medicamen Biotec - Corrigendun To The Outcome Of The Board Meeting - April 24, 2025

    25 Apr 2025, 5:58PM Corrigendum to the Outcome of the meeting of the Board Meeting of Board of Directors of Medicamen Biotech Limited (\the Company\) in accordance with R

  • Medicamen Biotec - Alteration Of Capital and Fund Raising-XBRL

    25 Apr 2025, 4:42PM MEDICAMEN BIOTECH LIMITED has informed the Exchange regarding Allotment of Securities

  • Medicamen Biotec - Outcome of Board Meeting

    25 Apr 2025, 4:38PM Medicamen Biotech Limited has informed the Exchange regarding Board meeting held on April 24, 2025. Revised Outcome

  • Medicamen Biotec - Board Meeting Outcome for Revised Outcome Of Board Meeting 24.04.2025

    25 Apr 2025, 4:33PM Revised outcome of Board Meeting - 24.04.2025

  • Medicamen Biotec - Outcome of Board Meeting

    25 Apr 2025, 12:33PM Medicamen Biotech Limited has informed the Exchange regarding Board meeting held on April 24, 2025.

  • Medicamen Biotec - Board Meeting Outcome for Outcome Of Board Meeting - April 24, 2025 (Allotment Of Securities)

    25 Apr 2025, 12:30PM Outcome of Board Meeting - April 24, 2025

  • Medicamen Biotec - Alteration Of Capital and Fund Raising-XBRL

    24 Apr 2025, 7:52PM MEDICAMEN BIOTECH LIMITED has informed the Exchange regarding Allotment of Securities

  • Medicamen Biotec - Outcome of Board Meeting

    24 Apr 2025, 7:37PM Medicamen Biotech Limited has informed the Exchange regarding Board meeting held on April 24, 2025 for allotment of 8,48,220 Equity Shares and 6,50,00

  • Medicamen Biotec - Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of Medicamen Biotech Limited In Acc

    24 Apr 2025, 7:33PM We wish to inform you that the Board of Directors of the Company at their meeting held today i.e Thursday, April 24, 2025 has inter alia considered an

  • Medicamen Biotec - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    23 Apr 2025, 12:35PM Medicamen Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Medicamen Biotec - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    23 Apr 2025, 12:30PM Certificate under Regulation 75 (5) of SEBI (DP) Regulations, 2018

  • Medicamen Biotec has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    19 Apr 2025, 5:50PM As of March 2025, 43.16% is owned by Indian Promoters and 56.84% by Public. <p align=justify> Top Promoter holding highest number of shares of Medicam

  • Medicamen Biotec - Updates

    8 Apr 2025, 5:37PM Medicamen Biotech Limited has informed the Exchange regarding 'Declaration under Regulation 31(4) of the Securities and Exchange Board of India (Subst

  • Medicamen Biotec - Disclosure Under Regulation 31(4) Of The Securities And Exchange Board Of India (Substantial Acquistion Of

    8 Apr 2025, 5:04PM Please find attached disclosure under Regulation 31(4) of SEBI (SAST) Regulation, 2011

  • Medicamen Biotec - General Updates

    8 Apr 2025, 1:17PM Medicamen Biotech Limited has informed the Exchange about General Updates

  • Medicamen Biotec - Announcement Under Regulation 30 (LODR) - Updates

    8 Apr 2025, 1:13PM Announcement under Regulation 30 (LODR)- Updates

  • Medicamen Biotec - General Updates

    3 Apr 2025, 12:10PM Medicamen Biotech Limited has informed the Exchange about General Updates

  • Medicamen Biotec - Announcment Under Regulation 30 (LODR)- Update

    3 Apr 2025, 12:06PM Announcement under Regulation 30 (LODR) - Update

  • Medicamen Biotech receives ANDA approval from the USFDA for Bortezomib Injection

    3 Jun 2025 , 1:58PM Bortezomib is used to treat Multiple Myeloma

  • Medicamen Biotech signs CDMO contract with XGX Pharm

    3 Apr 2025 , 1:30PM Medicamen Biotech signs CDMO contract with XGX Pharma to develop & manufacture 6 products
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Medicamen Biotech Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 244.6001 238.792 217.9787 172.3863 151.6863
Liabilities 244.6001 238.792 217.9787 172.3863 151.6863
Equity 12.7146 12.7146 12.6511 12.2166 12.2166
Gross Profit 16.5566 25.9708 24.1468 23.5554 19.5808
Net Profit 9.4591 13.298 15.002 14.9064 12.4866
Cash From Operating Activities -2.0088 -0.2462 -3.4985 4.8102 13.2862
NPM(%) 6.24 7.71 10.88 12.91 11.33
Revenue 151.4633 172.3862 137.884 115.4452 110.1465
Expenses 134.9067 146.4154 113.7372 91.8898 90.5656
ROE(%) 4.36 6.13 6.92 6.87 5.76

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
1 10 0.24 428.2
19 Sep 2024 1 10 0.24 506.95
20 Sep 2023 1 10 0.24 781.95
19 Sep 2022 1 10 0.24 607.05

Peers

Other companies within the same industry or sector that are comparable to Medicamen Biotech Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 877.60 4.96 29.12 237.73 301.39 0.57
Lotus Eye Hospital and Institute Ltd 71.05 -0.15 203.00 866.27 3.55 0.00
Vaishali Pharma Ltd 11.55 -0.43 192.50 446.51 3.13 0.00
Astec Lifesciences Ltd 943.00 1.98 0.00 816.82 -687.10 0.00

Company Info

MBL was incorporated as a public limited company under the Companies Act, 1956, on December 22, 1993. The certificate of commencement of business was obtained on January 31, 1994. The company has jointly been promoted by Mr.V.Kumar, Mr.Bal Kishan Gupta, Mr.Lakhvinder Singh Arora and Mr.Ranjit Singh. MBL is engaged in marketing of various drugs in the domestic and export markets. Company is procuring drugs from various reputed manufactures viz. Hoechst, Cadila, Hindustan Ciba, Purepharma, Oboi Labs etc. and exporting to countries like Germany, Russia, Holland, CIS (Confederation of Independent States) etc. part from domestic ethical and institutional sales. MBL has obtained permission for production of tablets, capsules and liquid orals under loan licence basis from Delhi Drug Control Authority and Madhya Pardesh Drug Control Authority on Welbeck Pharmaceutical Private Limited, New Delhi and Pure Pharma Private Limited, Indore respectively. 2010 -The Company has recommended a final dividend of Rs. 0.75 per equity share (being 7.5% on the face value of Rs. 10 per share) -The Company appointed Mr. B.K.Gupta as Managing Director. 2011 -The Company gets ANVISA.Brazil approval for Non Beta Lactum solid Tablets and Coated tablets manufactured at its Plant situated at SP 1192,A & B, Phase 4, Bhiwadi - 301019, Rajasthan. 2013 -Ms. Harshita Sharma has been appointed as Additional Director of the company. 2016 -Shivalik Rasayan Ltd take controlling stake of Medicamen Biotech Ltd. 2019 -FABD(Philippines), CECMED(Cuba)-Bhiwadi FDF Plant. 2020 -Global API Facility started Dahej API Plant. 2021 -Operations started Haridwar formulation Unit II(FDF). 2023 --Medicamen Biotech Gains On Successful Anda Filing For Bortezomib Injections. 2024 -Medicamen Biotech's Bhiwadi Manufacturing Facility Secures EU GMP Approval from Greece. -Medicamen Biotech's Sterile injectable Facility Received USFDA Approval.

MBL was incorporated as a public limited company under the Companies Act, 1956, on December 22, 1993. The certificate of commencement of business was obtained on January 31, 1994. The company has jointly been promoted by Mr.V.Kumar, Mr.Bal Kishan Gupta, Mr.Lakhvinder Singh Arora and Mr.Ranjit Singh. MBL is engaged in marketing of various drugs in the domestic and export markets. Company is procuring drugs from various reputed manufactures viz. Hoechst, Cadila, Hindustan Ciba, Purepharma, Oboi Labs etc. and exporting to countries like Germany, Russia, Holland, CIS (Confederation of Independent States) etc. part from domestic ethical and institutional sales. MBL has obtained permission for production of tablets, capsules and liquid orals under loan licence basis from Delhi Drug Control Authority and Madhya Pardesh Drug Control Authority on Welbeck Pharmaceutical Private Limited, New Delhi and Pure Pharma Private Limited, Indore respectively. 2010 -The Company has recommended a final dividend of Rs. 0.75 per equity share (being 7.5% on the face value of Rs. 10 per share) -The Company appointed Mr. B.K.Gupta as Managing Director. 2011 -The Company gets ANVISA.Brazil approval for Non Beta Lactum solid Tablets and Coated tablets manufactured at its Plant situated at SP 1192,A & B, Phase 4, Bhiwadi - 301019, Rajasthan. 2013 -Ms. Harshita Sharma has been appointed as Additional Director of the company. 2016 -Shivalik Rasayan Ltd take controlling stake of Medicamen Biotech Ltd. 2019 -FABD(Philippines), CECMED(Cuba)-Bhiwadi FDF Plant. 2020 -Global API Facility started Dahej API Plant. 2021 -Operations started Haridwar formulation Unit II(FDF). 2023 --Medicamen Biotech Gains On Successful Anda Filing For Bortezomib Injections. 2024 -Medicamen Biotech's Bhiwadi Manufacturing Facility Secures EU GMP Approval from Greece. -Medicamen Biotech's Sterile injectable Facility Received USFDA Approval.

Read More

Parent Organisation

Medicamen Biotech Ltd.

Founded

22/12/1993

Managing Director

Mr.Rahul Bishnoi

NSE Symbol

MEDICAMEQEQ

FAQ

The current price of Medicamen Biotech Ltd is ₹ 411.30.

The 52-week high for Medicamen Biotech Ltd is ₹ 420.00 and the 52-week low is ₹ 410.25.

The market capitalization of Medicamen Biotech Ltd is currently ₹ 557.91. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Medicamen Biotech Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Medicamen Biotech Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Medicamen Biotech Ltd shares.

The CEO of Medicamen Biotech Ltd is Mr.Rahul Bishnoi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT